The translational value is high because APOE4 remains the largest common genetic risk factor in Alzheimer disease, and microglial lipid biology is now actionable with existing genetic, pharmacologic, and single-cell tools. The most useful endpoint is not generic amyloid uptake. Drug developers need to know whether APOE4 changes plaque compaction, intracellular degradation, inflammatory injury, or all three. Those mechanisms imply different interventions and safety risks.
A feasible study would use APOE isogenic human iPSC microglia and an in vivo confirmation arm in APOE targeted-replacement amyloid mice. In vitro, combine fluorescent amyloid uptake/degradation reporters with lipidomics, lysosomal assays, and scRNA-seq or CITE-seq after exposure to fibrillar amyloid. In vivo, isolate plaque-associated microglia from APOE3 and APOE4 amyloid mice and quantify lipid droplets, cholesteryl esters, lysosomal markers, and plaque-associated amyloid burden. The Nature Immunology report that APOE4 can impair microglial response through TGF-beta-mediated checkpoints (DOI:10.1038/s41590-023-01627-6) is directly relevant because it suggests APOE4 may alter state transitions, not just lipid storage.
Therapeutically, I would prioritize mechanisms with CNS-restricted or cell-type-selective leverage. LXR agonists are useful probes but not necessarily the clinical answer. ABCA1/APOE lipidation, ACAT1/SOAT1, TREM2 signaling, and APOE lowering or silencing are all plausible comparators; APOE silencing has preclinical amyloid effects (PMID:38375983), but reducing APOE in humans must be evaluated carefully because APOE also has homeostatic lipid-transport roles. The best near-term product of this debate is a stratification biomarker: APOE4 lipid-droplet-high, lysosome-low microglia near plaques. Scientific priority: 0.79; translational readiness: 0.52.